Three Amino Acids Were Bolted On for One Reason: to Stop It Falling Apart

Short peptides have a durability problem. The body is full of enzymes whose job is taking peptides apart, and a molecule only a few residues long presents very little to hold onto. Plenty of interesting short peptides are interesting for about as long as it takes to degrade them.

Selank is what a direct answer to that problem looks like.

It starts as a piece of an antibody

The parent molecule is tuftsin, a four-residue peptide. Its origin is more surprising than its size: tuftsin is a fragment of the heavy chain of immunoglobulin G, which is to say a piece of an antibody.

That's already an odd lineage for something studied in the brain. An immune molecule gets cut down to four amino acids, and the fragment turns out to have activity of its own.

Tuftsin is also, in the phrase the literature uses, rapidly degraded. Which brings us to the modification.

Three residues, added at one end, for one stated reason

Selank is tuftsin with three more amino acids attached at the far end. That's the whole design.

The extension was added specifically to improve the molecule's metabolic stability, and to give it a longer duration of action than the parent it was built from. Not to change what it targets. Not to make it more potent. To make it last.

There's something clarifying about a modification with a single declared purpose. A lot of molecular design involves trade-offs nobody quite names. Here the intent is on the record, and it's narrow enough that you could in principle check whether it worked.

The work was done at the Institute of Molecular Genetics of the Russian Academy of Sciences. The compound carries both neuropeptide and immune-related activity, which follows directly from where it came from. A molecule descended from an antibody fragment doesn't stop being an immune peptide because you started studying it somewhere else.

Then the awkward finding

Here's where the story gets more interesting than a design note.

Volkova and colleagues reported in 2016 that giving Selank to rats changed the activity of several genes involved in a major inhibitory signaling system in the frontal cortex. That was in living animals, and the pattern of change resembled the pattern produced by the system's own natural signaling molecule.

Filatova and colleagues then asked the same question in cultured human cells in 2017, and got a different answer. Selank on its own produced no change at all in those genes.

No effect. Not a smaller effect, not a slower one. Nothing.

What it did do was change what something else was doing

The same experiment had a second arm, and that's where the result lives.

When Selank was combined with the natural signaling molecule, it suppressed most of the changes that molecule produced by itself. So in isolated cells it isn't acting on those genes directly. It's altering what happens when something else acts on them.

That reframes the compound. A molecule that does nothing alone and something in company isn't a weak version of an active drug. It's a different category of thing, and the honest description is a modulator rather than an actor.

A 2018 binding study by Vyunova and colleagues fits that reading. In assays on membranes from rat brain cells, Selank behaved as a positive allosteric modulator. That is the technical term for exactly this: a molecule that binds somewhere other than the main site and changes how that site responds. The site it bound appeared distinct from the one benzodiazepines use, though possibly overlapping in part.

A second mechanism, and a mouse strain that didn't play along

There's a separate strand that has nothing to do with the above, and it's better characterized.

Zozulya and colleagues reported in 2001 that Selank slows the enzymes that break down enkephalins, the body's own short opioid-like peptides. In that test it did so more effectively than two standard reference inhibitors. The proposal is that it prolongs signaling that is already happening rather than initiating any of its own. Which is, again, a modulator's job description.

Sokolov and colleagues followed in 2002 with the detail I'd keep. In a mouse strain prone to anxiety-like behavior, Selank produced an effect in an open-field test and lengthened the survival time of enkephalin in plasma. A different mouse strain showed neither response.

That's the sort of result that usually gets flattened into a single sentence about what a compound does in mice. Two strains, one responded, one didn't, and the paper said so.

The compound it's usually mentioned beside

Semax comes up in almost every discussion of Selank, and the pairing makes sense in one way and not in another.

Both came out of the same Russian research environment, and that environment generated most of the human data that exists for either. But they are built from different starting material. Selank descends from an antibody fragment. Semax descends from a fragment of a hormone. Two short peptides with unrelated parents, studied side by side largely because of where the work happened.

Why the design decision still matters

Come back to those three amino acids.

They were added so the molecule would survive long enough to act. Everything described above, the gene expression work, the binding behavior, the enkephalin strand, depends on there being enough intact peptide around to observe anything at all.

It's a small piece of engineering with an unglamorous goal, and it's the reason there's a literature here to discuss at all. The fuller account goes through what that literature does and doesn't establish, study by study.